52U Stock Overview
Engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Hyloris Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €15.86 |
| 52 Week High | €18.60 |
| 52 Week Low | €12.75 |
| Beta | 0.58 |
| 11 Month Change | 0% |
| 3 Month Change | -1.74% |
| 1 Year Change | 19.25% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 54.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 52U | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.02% |
| 1Y | 19.2% | -20.1% | 8.2% |
Return vs Industry: 52U exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 52U exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 52U volatility | |
|---|---|
| 52U Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 52U has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 52U's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 21 | Stijn Van Rompay | hyloris.com |
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women’s health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection.
Hyloris Pharmaceuticals SA Fundamentals Summary
| 52U fundamental statistics | |
|---|---|
| Market cap | €379.49m |
| Earnings (TTM) | -€11.58m |
| Revenue (TTM) | €3.10m |
122.6x
P/S Ratio-32.8x
P/E RatioIs 52U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 52U income statement (TTM) | |
|---|---|
| Revenue | €3.10m |
| Cost of Revenue | €107.00k |
| Gross Profit | €2.99m |
| Other Expenses | €14.57m |
| Earnings | -€11.58m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 01, 2022
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 96.54% |
| Net Profit Margin | -374.00% |
| Debt/Equity Ratio | 17.9% |
How did 52U perform over the long term?
See historical performance and comparison